通过基于生理学的药动学(physiologically based pharmacokinetic,PBPK)建模策略预测晶型Ⅰ与晶型Ⅱ利福平在人体内的药动学行为,判断两者是否生物等效。对两种晶型利福平进行体外研究后,以大鼠静脉给药的药动学数据为基础,构建大鼠PBP...通过基于生理学的药动学(physiologically based pharmacokinetic,PBPK)建模策略预测晶型Ⅰ与晶型Ⅱ利福平在人体内的药动学行为,判断两者是否生物等效。对两种晶型利福平进行体外研究后,以大鼠静脉给药的药动学数据为基础,构建大鼠PBPK模型,再通过大鼠口服给药的药动学数据进行模型优化,种属外推至健康人体,利用外推模型预测两种晶型的利福平在健康人体内的血药浓度-时间曲线、吸收部位及吸收量等药动学行为。健康人体模型预测结果显示,晶型Ⅰ与晶型Ⅱ利福平的c_(max)分别为8.42和10.35μg/mL,t_(max)分别为0.40和0.32 h,AUC_(0-t)均为62.90μg·h/mL。根据吸收情况预测结果,晶型Ⅰ与晶型Ⅱ利福平在胃部均不被吸收,但在肠道被完全吸收,两者吸收部位及吸收量基本一致。晶型Ⅰ与晶型Ⅱ利福平的药动学参数十分接近,预测两者具有生物等效性。展开更多
In this study,we aimed to develop and evaluate a whole-body physiologically based pharmacokinetic(WB-PBPK)/pharmacodynamic(PD)model for saxagliptin,simulate its pharmacokinetic and pharmacodynamic properties in health...In this study,we aimed to develop and evaluate a whole-body physiologically based pharmacokinetic(WB-PBPK)/pharmacodynamic(PD)model for saxagliptin,simulate its pharmacokinetic and pharmacodynamic properties in healthy adults and patients with hepatic function impairment,and provide a new method for the research to the clinical pharmacy of special patients.Based on the drug-specific properties,such as log D,plasma protein binding collected by the published literature,the WB-PBPK model and the PD model were established.After comparing the simulated concentration-time profiles and the pharmacokinetic parameters with data in healthy adults from oral and intravenous clinical investigation,the WB-PBPK model could be optimized.After comparing the simulated DPP-4 inhibition profile with the observed pharmacodynamic in healthy subjects,the PD model could be optimized.The PK/PD model was utilized to predict the mean and variability of the pharmacokinetic and pharmacodynamic profiles in subjects with different hepatic impairment.All of the predicted pharmacokinetic curves were comparable to the observed curves both in healthy subjects and hepatic impairment subjects(Cmax and AUC were less than 1.3-fold).The predicted pharmacodynamic curves were comparable to the observed ones in different oral dosage after optimization,and pharmacodynamics of saxagliptin in hepatic impairment subjects were predicted successfully.The WB-PBPK/PD model can accurately simulate the pharmacokinetics and pharmacodynamics of saxagliptin in normal adults and different hepatic impaired patients.展开更多
文摘通过基于生理学的药动学(physiologically based pharmacokinetic,PBPK)建模策略预测晶型Ⅰ与晶型Ⅱ利福平在人体内的药动学行为,判断两者是否生物等效。对两种晶型利福平进行体外研究后,以大鼠静脉给药的药动学数据为基础,构建大鼠PBPK模型,再通过大鼠口服给药的药动学数据进行模型优化,种属外推至健康人体,利用外推模型预测两种晶型的利福平在健康人体内的血药浓度-时间曲线、吸收部位及吸收量等药动学行为。健康人体模型预测结果显示,晶型Ⅰ与晶型Ⅱ利福平的c_(max)分别为8.42和10.35μg/mL,t_(max)分别为0.40和0.32 h,AUC_(0-t)均为62.90μg·h/mL。根据吸收情况预测结果,晶型Ⅰ与晶型Ⅱ利福平在胃部均不被吸收,但在肠道被完全吸收,两者吸收部位及吸收量基本一致。晶型Ⅰ与晶型Ⅱ利福平的药动学参数十分接近,预测两者具有生物等效性。
文摘In this study,we aimed to develop and evaluate a whole-body physiologically based pharmacokinetic(WB-PBPK)/pharmacodynamic(PD)model for saxagliptin,simulate its pharmacokinetic and pharmacodynamic properties in healthy adults and patients with hepatic function impairment,and provide a new method for the research to the clinical pharmacy of special patients.Based on the drug-specific properties,such as log D,plasma protein binding collected by the published literature,the WB-PBPK model and the PD model were established.After comparing the simulated concentration-time profiles and the pharmacokinetic parameters with data in healthy adults from oral and intravenous clinical investigation,the WB-PBPK model could be optimized.After comparing the simulated DPP-4 inhibition profile with the observed pharmacodynamic in healthy subjects,the PD model could be optimized.The PK/PD model was utilized to predict the mean and variability of the pharmacokinetic and pharmacodynamic profiles in subjects with different hepatic impairment.All of the predicted pharmacokinetic curves were comparable to the observed curves both in healthy subjects and hepatic impairment subjects(Cmax and AUC were less than 1.3-fold).The predicted pharmacodynamic curves were comparable to the observed ones in different oral dosage after optimization,and pharmacodynamics of saxagliptin in hepatic impairment subjects were predicted successfully.The WB-PBPK/PD model can accurately simulate the pharmacokinetics and pharmacodynamics of saxagliptin in normal adults and different hepatic impaired patients.
